Business brief
Cardiovascular Drug Setback Hits Novartis as Eli Lilly Drives $32B M&A Spree
Novartis and Ionis hit a late-stage trial failure, Volkswagen flags 50,000 job cuts, and Eli Lilly outspends big pharma rivals combined.
Business
Volkswagen is forcing structural retrenchment — planning 50,000 job cuts to survive fierce Chinese competition and rising production costs.
BackgroundEuropean automakers face structural challenges as high local energy prices, declining market share in China, and strict electric vehicle mandates pressure corporate margins. Volkswagen operates extensive manufacturing networks across Germany subject to strict labor agreements.
- The restructuring plan flags up to 50,000 workforce reductions while assessing manufacturing allocations across 4 German factories to lower fixed operating costs.
- Management aims to generate $11 billion in operational savings through factory consolidation and reduced research spending to preserve operating margins.
- German labor unions and European works councils promised aggressive resistance against factory closures and forced layoffs, setting up months of protracted labor standoffs.
Business
Lowering target cholesterol failed to prevent heart attacks — shattering investor expectations for a new class of cardiovascular blockbusters.
BackgroundPelacarsen was designed to lower lipoprotein(a), an inherited type of cholesterol linked to premature cardiovascular disease. Major drugmakers are investing heavily in Lp(a)-lowering therapies to secure new blockbuster drugs before key patents expire.
- Although pelacarsen reduced blood levels of lipoprotein(a), it failed to reduce overall heart attacks, strokes, or cardiovascular deaths, raising fundamental doubts about the target biomarker.
- The clinical trial failure removes a key late-stage growth asset for Novartis as the pharmaceutical giant faces upcoming patent expiries on top-selling medications.
- Rival drugmaker Amgen dropped 5% following news of the trial, as investors questioned whether rival Lp(a)-lowering pipeline candidates can demonstrate actual clinical benefit.
Business
Business
Eli Lilly is using GLP-1 profits to buy up late-stage biotech rivals — outspending the rest of big pharma combined to dominate pipeline acquisition.
BackgroundEli Lilly has generated unprecedented cash flows from its market-leading GLP-1 weight-loss and diabetes treatments Zepbound and Mounjaro. Pharmaceutical companies use windfall profits from top-selling drugs to acquire early-stage biotech pipelines before existing patents expire.
- Lilly's 13 acquisitions in 2026 reached $32 billion, outpacing the combined M&A spending of its 11 largest global drug rivals.
- Cash flows from GLP-1 obesity treatments are being deployed directly into acquiring late-stage clinical biotech startups to reinforce future drug revenue.
- Investment analysts expect Lilly to continue acquiring clinical assets across immunology, metabolic health, and genetic medicine throughout the remainder of the year.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
